An abnormal TGF-β/SMAD pathway can promote the migration of cancer cells by evading immune surveillance, inhibit apoptosis, promote tumor angiogenesis by regulating the expression of VEGF, and induce EMT in late tumor stages (165). Here, TGFB1 is linked to neoplasm.